Healthcare provider profile · identity verified

Meera Mohanakumar, MD

Family Practice · EVERETT, WA · NPI 1598858417

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	356	53
Lisinopril	Lisinopril	251	44
Losartan Potassium	Losartan Potassium	190	25
Amlodipine Besylate	Amlodipine Besylate	180	29
Levothyroxine Sodium	Levothyroxine Sodium	165	25
Metoprolol Succinate	Metoprolol Succinate	142	19
Gabapentin	Gabapentin	137	18
Metformin Hcl Er	Metformin Hcl	119	20
Montelukast Sodium	Montelukast Sodium	115	14
Rosuvastatin Calcium	Rosuvastatin Calcium	115	14
Albuterol Sulfate Hfa	Albuterol Sulfate	97	32
Pantoprazole Sodium	Pantoprazole Sodium	86	14
Eliquis	Apixaban	83	suppressed
Fluticasone Propionate	Fluticasone Propionate	82	25
Hydrochlorothiazide	Hydrochlorothiazide	77	14
Famotidine	Famotidine	75	suppressed
Omeprazole	Omeprazole	74	14
Trazodone Hcl	Trazodone Hcl	62	suppressed
Xarelto	Rivaroxaban	62	suppressed
Metformin Hcl	Metformin Hcl	57	suppressed
Farxiga	Dapagliflozin Propanediol	53	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	53	suppressed
Finasteride	Finasteride	49	suppressed
Meloxicam	Meloxicam	44	suppressed
Sertraline Hcl	Sertraline Hcl	44	suppressed
Mirtazapine	Mirtazapine	43	suppressed
Lansoprazole	Lansoprazole	42	suppressed
Jardiance	Empagliflozin	39	suppressed
Chlorthalidone	Chlorthalidone	36	suppressed
Glipizide Er	Glipizide	34	suppressed
Januvia	Sitagliptin Phosphate	34	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	32	suppressed
Furosemide	Furosemide	29	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Potassium Chloride	Potassium Chloride	27	suppressed
Spironolactone	Spironolactone	26	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	26	suppressed
Baclofen	Baclofen	25	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Torsemide	Torsemide	25	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	21	suppressed
Alendronate Sodium	Alendronate Sodium	19	suppressed
Carvedilol	Carvedilol	19	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Spiriva Respimat	Tiotropium Bromide	18	suppressed
Atenolol	Atenolol	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Prednisone	Prednisone	17	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Simvastatin	Simvastatin	16	suppressed
Tresiba Flextouch U-200	Insulin Degludec	16	suppressed
Digoxin	Digoxin	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Calcitriol	Calcitriol	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	13	suppressed
Fluconazole	Fluconazole	13	suppressed
Naltrexone Hcl	Naltrexone Hcl	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Restasis	Cyclosporine	13	suppressed
Roflumilast	Roflumilast	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	12	suppressed
Allopurinol	Allopurinol	12	suppressed
Aspirin-Dipyridamole Er	Aspirin/Dipyridamole	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Cilostazol	Cilostazol	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Ozempic	Semaglutide	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error